Skip Navigation

This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (1)
Right arrow Request Permissions
Google Scholar
Right arrow Articles by Matsumura, Y.
Right arrow Articles by Sugano, K.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Matsumura, Y.
Right arrow Articles by Sugano, K.
Social Bookmarking
 Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Japanese Journal of Clinical Oncology 32:9-13 (2002)
© 2002 Foundation for Promotion of Cancer Research

Effect of a 3-hour Interval Between Methotrexate and 5-Fluorouracil in the Treatment of Metastatic Colorectal Cancer

Yasuhiro Matsumura, Kunio Haruyama, Tetsuya Hamaguchi, Kuniaki Shirao, Kei Muro, Yasuhide Yamada, Yasuhiro Shimada and Kokichi Sugano+

Division of Gastrointestinal Oncology, Department of Medicine, National Cancer Center Hospital, Tokyo, Japan

Objective: This phase II study was designed to evaluate the efficacy and toxicity of 3-h interval sequential methotrexate (MTX) and 5-fluorouracil (5-FU) with leucovorin (LV) rescue in the treatment of patients with metastatic colorectal cancer.

Methods: Forty-two patients with histologically confirmed metastatic colorectal cancer and at least one two-dimensionally measurable lesion, aged 30–74 years old, with performance status <=2 and no or one prior chemotherapy were selected. Patients received sequential MTX 100 mg/m2 by bolus injection and 5-FU 600 mg/m2 at 3 h followed by LV rescue initiated after 24 h (15 mg per body every 6 h for six doses). The treatment was repeated every week or every 2 weeks until disease progression. All patients were treated as out-patients unless complications arose.

Results: All 42 patients entered in this study were assessable both for response and toxicity. Fifteen patients achieved objective responses (one complete and 14 partial), for an overall response rate of 36% (95% CI: 11–51%). Response rates in pretreated patients and patients with naive chemotherapy were 27 and 42%, respectively. Sixteen patients had stable disease and 11 progressed with therapy. The median survival for all patients was 378 days. The hematological toxicity was mild with no grade 3/4 leukopenia. The major non-hematological toxicity was diarrhea (one grade 4, four grade 3).

Conclusions: This 3-h interval sequential MTX and 5-FU with LV rescue is an active regimen in patients with metastatic colorectal cancer. The treatment showed mild toxicity and was administered on an out-patient basis. The present findings suggest that this regimen warrants further investigation in patients with metastatic colorectal cancer.

+ For reprints and all correspondence: Yasuhiro Matsumura, Division of Gastrointestinal Oncology, Department of Medicine, National Cancer Center Hospital, 1–1 Tsukiji 5-chome, Chuo-ku, Tokyo 104-0045, Japan. E-mail: yhmatsum@ncc.go.jp


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
Jpn J Clin OncolHome page
A. Hosokawa, Y. Yamada, Y. Shimada, K. Muro, Y. Matsumura, S. Fujita, T. Akasu, Y. Moriya, and K. Shirao
Weekly Hepatic Arterial Infusion of 5-Fluorouracil and Subsequent Systemic Chemotherapy for Liver Metastases from Colorectal Cancer
Jpn. J. Clin. Oncol., March 1, 2003; 33(3): 132 - 135.
[Abstract] [Full Text] [PDF]



Disclaimer:
Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.